BMJ  2004;329:1294 (27 November), doi:10.1136/bmj.329.7477.1294

reviews

Press

Fix for low sex drive puts reporters in a bad patch

Stories about the testosterone patch are a case study in misleading media coverage

The first 150 words of the full text of this article appear below.

As the debate over the safety of new anti-arthritis drugs rolls around the world, the gap between marketing messages and scientific truths becomes clearer by the day. The estimated toll of heart attacks associated with Merck's rofecoxib (Vioxx) mounts; questions about other COX 2 inhibitors arise; and the drug companies and regulators are rightly being criticised and investigated. Now is a good time for rigorous scrutiny of the media's role in initially boosting this new class of anti-arthritis drugs: the record will show that many reporters seemed simply to reproduce the marketing hype in their stories.

Yet even while this debacle continues, another case study in misleading media coverage around the world is fast emerging: many of the articles about the experimental testosterone patch for women look more like marketing fiction than rigorous journalism. In their search for sexy stories some media outlets are exaggerating the benefits of the . . . [Full text of this article]

-->

BMJ raymond.moynihan@verizon.net

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Is drug regulation failing?

Kamran Abbasi
BMJ 2004 329: 0. [Extract] [Full Text] [PDF]

Drug maker urges group to lobby FDA on testosterone for women

Ray Moynihan
BMJ 2004 329: 1255. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

New Scientist did declare drug company funding

Damian Carrington
bmj.com, 7 Dec 2004 [Full text]

Online poll

Find out more here>> and here>>